|
US8343966B2
(en)
*
|
2008-01-11 |
2013-01-01 |
Novartis Ag |
Organic compounds
|
|
US20110257171A1
(en)
*
|
2008-07-18 |
2011-10-20 |
Sanofi-Aventis |
Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
|
|
FR2945806B1
(fr)
*
|
2009-05-19 |
2013-04-05 |
Sanofi Aventis |
Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
|
|
CA2760778A1
(en)
*
|
2009-05-13 |
2010-11-18 |
Amgen Inc. |
Heteroaryl compounds as pikk inhibitors
|
|
CN102471345A
(zh)
*
|
2009-07-15 |
2012-05-23 |
雅培制药有限公司 |
激酶的吡咯并吡嗪抑制剂
|
|
UY33213A
(es)
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
WO2011146287A1
(en)
|
2010-05-20 |
2011-11-24 |
Takeda Pharmaceutical Company Limited |
Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5
|
|
CN102443009B
(zh)
*
|
2010-09-30 |
2014-04-16 |
山东轩竹医药科技有限公司 |
并环激酶抑制剂
|
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
WO2013004551A1
(en)
*
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
|
|
EP2554544A1
(en)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1h)-one derivatives as jak inhibitors
|
|
US9012450B2
(en)
|
2011-12-28 |
2015-04-21 |
Global Blood Therapeutics, Inc. |
Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
|
|
PL2797416T3
(pl)
*
|
2011-12-28 |
2017-12-29 |
Global Blood Therapeutics, Inc. |
Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
|
|
GB201205669D0
(en)
*
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
JP6430383B2
(ja)
*
|
2012-09-28 |
2018-11-28 |
ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ |
選択的ｂｍｐ阻害剤としての縮合複素環化合物
|
|
US10266551B2
(en)
|
2013-03-15 |
2019-04-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US8952171B2
(en)
|
2013-03-15 |
2015-02-10 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9604999B2
(en)
|
2013-03-15 |
2017-03-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
EP2968299B1
(en)
|
2013-03-15 |
2021-01-20 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9422279B2
(en)
|
2013-03-15 |
2016-08-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
JP6426694B2
(ja)
|
2013-03-15 |
2018-11-21 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
ヘモグロビンの修飾のための化合物及びその使用
|
|
WO2014145040A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
|
|
US20140274961A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
BR112015021982B1
(pt)
|
2013-03-15 |
2022-12-13 |
Global Blood Therapeutics, Inc |
Compostos e seus usos para a modulação de hemoglobina
|
|
US9802900B2
(en)
|
2013-03-15 |
2017-10-31 |
Global Blood Therapeutics, Inc. |
Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
|
|
US9458139B2
(en)
|
2013-03-15 |
2016-10-04 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2015031285A1
(en)
*
|
2013-08-27 |
2015-03-05 |
Global Blood Therapeutics, Inc. |
Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
|
|
EA201992707A1
(ru)
|
2013-11-18 |
2020-06-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
|
AP2016009261A0
(en)
|
2014-02-07 |
2016-06-30 |
Global Blood Therapeutics Inc |
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MA41841A
(fr)
|
2015-03-30 |
2018-02-06 |
Global Blood Therapeutics Inc |
Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
|
|
US10836742B2
(en)
|
2015-08-11 |
2020-11-17 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
HK1256753A1
(zh)
|
2015-08-11 |
2019-10-04 |
Neomed Institute |
芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
|
|
CN114605387A
(zh)
|
2015-08-12 |
2022-06-10 |
埃皮吉纳提克斯股份有限公司 |
取代的苯并咪唑、它们的制备和它们作为药物的用途
|
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
|
PL3383392T3
(pl)
|
2015-12-04 |
2025-11-17 |
Global Blood Therapeutics, Inc. |
Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
|
|
WO2017127930A1
(en)
|
2016-01-28 |
2017-08-03 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
|
|
TWI663160B
(zh)
|
2016-05-12 |
2019-06-21 |
全球血液治療公司 |
用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
|
|
US11352328B2
(en)
|
2016-07-12 |
2022-06-07 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus
|
|
WO2018053126A1
(en)
*
|
2016-09-14 |
2018-03-22 |
Vanderbilt University |
Inhibition of bmp signaling, compounds, compositions and uses thereof
|
|
TW202332423A
(zh)
|
2016-10-12 |
2023-08-16 |
美商全球血液治療公司 |
包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
WO2019178383A1
(en)
|
2018-03-14 |
2019-09-19 |
Vanderbilt University |
Inhibition of bmp signaling, compounds, compositions and uses thereof
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
|
US12419865B2
(en)
|
2018-12-06 |
2025-09-23 |
Arisan Therapeutics Inc. |
Compounds for the treatment of arenavirus infection
|
|
JP7414827B2
(ja)
*
|
2018-12-20 |
2024-01-16 |
インサイト・コーポレイション |
アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12378241B2
(en)
*
|
2019-07-26 |
2025-08-05 |
Cgenetech (Suzhou,China) Co., Ltd. |
Pyridine derivative as FGFR and VEGFR dual inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
BR112022006394A2
(pt)
|
2019-10-02 |
2022-07-26 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN111116582B
(zh)
*
|
2019-12-18 |
2022-07-29 |
大连大学 |
一种mGluR2拮抗剂
|
|
WO2021123174A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Universite De Strasbourg |
Sigma-1 receptor ligands and therapeutic uses thereof
|
|
CN115052663B
(zh)
|
2020-01-08 |
2026-06-09 |
辛瑟斯治疗股份有限公司 |
Alk5抑制剂缀合物及其用途
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN114728965B
(zh)
*
|
2020-01-21 |
2024-05-28 |
四川科伦博泰生物医药股份有限公司 |
吡啶并杂环类化合物、其制备方法及用途
|
|
US11840546B2
(en)
|
2020-06-12 |
2023-12-12 |
Incyte Corporation |
Imidazopyridazine compounds and uses thereof
|
|
WO2021260110A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
|
AU2021298154A1
(en)
|
2020-06-25 |
2023-02-23 |
Tolremo Therapeutics Ag |
Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
|
|
EP4182323B1
(en)
|
2020-07-15 |
2024-04-24 |
Chiesi Farmaceutici S.p.A. |
Pyrido oxazine amino derivatives as alk5 inhibitors
|
|
EP4182322B1
(en)
|
2020-07-15 |
2024-04-24 |
Chiesi Farmaceutici S.p.A. |
Pyrido oxazine derivatives as alk5 inhibitors
|
|
PT4182308T
(pt)
|
2020-07-15 |
2024-12-04 |
Chiesi Farm Spa |
Derivados de piridazinil amino como inibidores de alk5
|
|
WO2022136221A1
(en)
|
2020-12-23 |
2022-06-30 |
Chiesi Farmaceutici S.P.A. |
Pyrido oxazine derivatives as alk5 inhibitors
|
|
WO2022161408A1
(zh)
*
|
2021-01-26 |
2022-08-04 |
南京明德新药研发有限公司 |
甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
|
|
CA3212085C
(en)
|
2021-04-07 |
2025-02-11 |
Tolremo Therapeutics Ag |
HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3232178A1
(en)
|
2021-09-21 |
2023-03-30 |
Daniela PIZZIRANI |
Pyridazinyl amino derivatives as alk5 inhibitors
|
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
|
US20250270215A1
(en)
|
2022-04-27 |
2025-08-28 |
Chiesi Farmaceutici S.P.A. |
Imidazole derivatives as alk5 inhibitors
|
|
IL320031A
(en)
|
2022-10-03 |
2025-06-01 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
WO2024209035A1
(en)
|
2023-04-05 |
2024-10-10 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
WO2024258967A1
(en)
|
2023-06-13 |
2024-12-19 |
Synthis Therapeutics, Inc. |
Anti-cd5 antibodies and their uses
|
|
KR20260084620A
(ko)
|
2023-10-03 |
2026-06-05 |
포알엑스 테라퓨틱스 아게 |
Parg 억제 화합물
|